12 Oversold NASDAQ Stocks to Buy Now
On July 14, Max Kettner, chief multi-asset strategist at HSBC, appeared on CNBC to talk about the global markets amid trade tensions.
Viking Therapeutics Inc. (VKTX)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | 2,938,800 | $70,972,020 | +543% | 0.12% | |
| 2. | Citadel Investment Group Ken Griffin | 1,651,090 | $39,873,823 | +12% | 0.01% |
| 3. | Balyasny Asset Management Dmitry Balyasny | 1,648,628 | $39,814,366 | +92% | 0.07% |
| 4. | Braidwell LP Alex Karnal | 1,435,955 | $34,678,313 | -3% | 1.22% |
| 5. | 1,319,600 | $31,868,340 | +110% | 0.01% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $24.15 | 1,240 | $29,942.78 | 1,240 | 2025-03-31 | Filing | |
| $24.15 | 1,240 | $29,942.78 | 1,240 | 2025-03-31 | Filing | |
| $2.47 | 45,000 | $111,195.00 | 111,250 | 2022-05-02 | Filing | |
| $5.69 | 20,000 | $113,800.00 | 66,250 | 2021-06-10 | Filing | |
| $9.82 | 9,500 | $93,260.55 | 9,500 | 2018-05-31 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $27.80 | 26,889 | $747,632.51 | 2,388,014 | 2025-07-03 | Filing | |
| $27.76 | 4,266 | $118,428.43 | 168,660 | 2025-07-03 | Filing | |
| $27.77 | 4,266 | $118,472.79 | 377,535 | 2025-07-03 | Filing | |
| $43.32 | 19,000 | $823,021.10 | 2,366,570 | 2025-01-06 | Filing | |
| $42.68 | 175,490 | $7,490,580.06 | 2,385,570 | 2025-01-06 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 116,852 | $3,096,576 | 2.79% | |
| 2. | 90,377 | $2,394,991 | 0.27% | |
| 3. | 63,546 | $1,683,969 | 0.05% | |
| 4. | 53,514 | $1,418,121 | 0.02% | |
| 5. | 52,000 | $1,378,000 | 0.04% |
News See All
Viking Therapeutics (VKTX) Soars 9.7% on Looming Weight Loss Drug Trial Results
Viking Therapeutics jumped by 9.74 percent on Tuesday to close at $30.19 apiece as investors repositioned portfolios ahead of the expected release of the results of its own weight loss drug clinical trial...
Viking Therapeutics (VKTX) Rises on Expected Developments
We recently published a list of Investors Are Gobbling Up Shares of These 10 Firms.
Was Jim Cramer Right to Favor Another Stock Over Viking Therapeutics (VKTX)?
We recently published a list of Jim Cramer Nailed These 11 Stock Predictions. In this article, we are going to take a look at where Viking Therapeutics, Inc.
Jim Cramer Nailed These 11 Stock Predictions
“There are many reasons why Trump won November. inflation, immigration, culture war backlash.
20 Takeover Rumors Hedge Funds Are Buying
Hedge funds tend to pile up on a stock that gains or is expected to gain positive attention in a market.
10 Worst Performing Mid Cap Stocks to Buy According to Analysts
Market analysts are increasingly highlighting mid-cap stocks as a potentially attractive investment opportunity, particularly in the current economic climate.
Viking Therapeutics, Inc. (VKTX): A Bull Case Theory
We came across a bullish thesis on Viking Therapeutics, Inc. (VKTX) on Substack by Kontra Investments. In this article, we will summarize the bulls’ thesis on VKTX. Viking Therapeutics, Inc.
10 Oversold Biotech Stocks to Buy Now
Biotechnology stocks are among the most volatile in the market, primarily due to the high risks associated with their performance.
15 Stocks That Took a Nosedive in January
Historically, the S&P 500's performance in January sets the pace for the rest of the year.
Billionaire Hedge Funds
